Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. Di Leo A, et al. Among authors: dolci s. Clin Cancer Res. 2002 May;8(5):1107-16. Clin Cancer Res. 2002. PMID: 12006526 Clinical Trial.
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Piccart MJ, et al. Among authors: dolci s. J Clin Oncol. 2001 Jun 15;19(12):3103-10. doi: 10.1200/JCO.2001.19.12.3103. J Clin Oncol. 2001. PMID: 11408507 Clinical Trial.
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.
Ferreira Filho AF, Di Leo A, Paesmans M, Beauduin M, Vindevoghel A, Michel J, Focan C, Awada A, Cardoso F, Dolci S, Bartholomeus S, Piccart MJ. Ferreira Filho AF, et al. Among authors: dolci s. Ann Oncol. 2002 Mar;13(3):416-21. doi: 10.1093/annonc/mdf051. Ann Oncol. 2002. PMID: 11996473 Free article. Clinical Trial.
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. de Azambuja E, et al. Among authors: dolci s. J Clin Oncol. 2009 Feb 10;27(5):720-5. doi: 10.1200/JCO.2008.17.2155. Epub 2008 Dec 22. J Clin Oncol. 2009. PMID: 19103732 Clinical Trial.
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S. Bozovic-Spasojevic I, et al. Among authors: dolci s. Breast. 2014 Aug;23(4):473-81. doi: 10.1016/j.breast.2014.03.012. Epub 2014 Apr 24. Breast. 2014. PMID: 24768477 Free article.
141 results